悦康药业(688658) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥1,041,759,196.79, representing a year-on-year increase of 37.47%[2] - The net profit attributable to shareholders for the same period was ¥91,171,550.09, with a year-to-date increase of 37.73% to ¥209,725,063.28[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥85,118,740.84 for Q3 2024, reflecting a year-to-date increase of 45.90%[2] - The basic earnings per share for Q3 2024 was ¥0.20, with a year-to-date increase of 38.24% to ¥0.47[3] - The net profit for Q3 2024 was CNY 208,200,539.69, an increase of 34.6% compared to CNY 154,624,259.72 in Q3 2023[15] - The total profit for Q3 2024 reached CNY 248,270,396.38, up 49.7% from CNY 165,761,105.35 in the same period last year[15] - Basic and diluted earnings per share for Q3 2024 were both CNY 0.47, compared to CNY 0.34 in Q3 2023, reflecting a 38.2% increase[16] Research and Development - Research and development expenses totaled ¥112,369,396.17 in Q3 2024, a decrease of 8.23% compared to the previous year[3] - Research and development expenses increased to CNY 261,146,138.06, up from CNY 231,721,009.40, indicating a growth of approximately 12.65%[14] Assets and Liabilities - The total assets of the company at the end of the reporting period were ¥6,003,710,202.69, an increase of 1.56% from the end of the previous year[3] - The company's total assets rose to CNY 6,003,710,202.69, compared to CNY 5,911,276,401.80, marking an increase of about 1.56%[13] - Non-current liabilities increased significantly to CNY 569,106,848.05 from CNY 177,004,400.11, showing a growth of approximately 221.51%[13] - The total liabilities of the company stood at CNY 2,331,799,871.26, slightly up from CNY 2,313,636,835.67, reflecting an increase of about 0.78%[13] - The equity attributable to shareholders of the parent company increased to CNY 3,663,638,001.19 from CNY 3,587,842,712.30, representing a growth of approximately 2.11%[13] - Short-term borrowings decreased significantly to CNY 202,715,515.62 from CNY 351,773,409.45, a reduction of about 42.36%[13] Cash Flow - The company reported a net cash flow from operating activities of ¥430,485,846.40 year-to-date, showing a decrease of 13.19% compared to the previous year[3] - Cash flow from operating activities for the first three quarters of 2024 was CNY 430,485,846.40, down 13.2% from CNY 495,894,226.56 in the same period of 2023[17] - Cash inflow from operating activities totaled CNY 3,326,912,990.09, a decrease of 9.5% compared to CNY 3,679,239,176.01 in the previous year[17] - Cash outflow from operating activities was CNY 2,896,427,143.69, down 9.0% from CNY 3,183,344,949.45 in the same period last year[17] - The company reported a net cash outflow from investing activities of CNY -320,111,188.83 for Q3 2024, compared to CNY -417,529,083.75 in Q3 2023[18] - Cash inflow from financing activities was CNY 523,673,304.58, an increase from CNY 346,555,000.00 in the same period last year[18] - The ending cash and cash equivalents balance for Q3 2024 was CNY 1,481,155,046.28, up from CNY 1,259,316,093.61 at the end of Q3 2023[18] - The company experienced a net increase in cash and cash equivalents of CNY 107,621,855.99 in Q3 2024, contrasting with a decrease of CNY -259,028,788.09 in Q3 2023[18] Shareholder Information - The top shareholder, Fuyang Jingyue Yongshun Information Consulting Co., Ltd., holds 40.05% of the shares, totaling 180,240,120 shares[8] - The company has no significant changes in the participation of major shareholders in margin trading or securities lending activities[9] - There are no reported related party transactions or agreements among the top shareholders, ensuring transparency in ownership[8] Business Developments - The company experienced significant sales growth in cardiovascular and digestive products, contributing to the increase in revenue and profit[6] - The company has not disclosed any new product developments or technological advancements during this reporting period[10] - There are no significant mergers or acquisitions reported in the third quarter of 2024[10] - The company has not provided specific future guidance or performance outlook for the upcoming quarters[10] Operating Costs - Total operating revenue for the first three quarters of 2024 reached CNY 2,991,795,632.65, a slight increase from CNY 2,957,716,328.49 in the same period of 2023, representing a growth of approximately 1.15%[14] - Total operating costs decreased to CNY 2,730,072,277.72 from CNY 2,787,559,797.21, reflecting a reduction of about 2.06%[14] - The company reported a decrease in sales expenses to CNY 1,077,257,545.89 from CNY 1,301,988,273.28, indicating a decline of approximately 17.25%[14] - Deferred income increased to CNY 102,240,785.31 from CNY 93,047,088.33, reflecting an increase of about 9.66%[13]